Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Abroad (travel likely)RecruitingPHASE1

Conditions

SLE (Systemic Lupus) · Sjogren's Syndrome · Systemic Scleroderma · Dermatomyositis · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Shanxi Bethune Hospital, Taiyuan, Shanxi, China
Contact: Study coordinator (Liyun Zhang, MD) · 1315710223@qq.com · 13834547708

Study leads

Liyun Zhang, M.D
Principal Investigator
Shanxi Bethune Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus · Lupus Nephritis (LN) · Sjogren's Syndrome

Abroad (travel likely)RecruitingPHASE1

Bengbu, China

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Sjogren's Syndrome (SS)

Abroad (travel likely)RecruitingPHASE1

Xuzhou, China · Xuzhou, China

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Lupus Nephritis (LN) · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE1

Hefei, China

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE) · Sjogren's Syndrome (SS) · Systemic Sclerosis (SSc)

Abroad (travel likely)RecruitingPHASE1

Shanghai, China